SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

A National Strategy to Improve Sexual Health

By Leave a Comment

JAMA

Andrea Swartzendruber, MPH; Jonathan M. Zenilman, MD
JAMA. 2010;304(9):1005-1006. doi:10.1001/jama.2010.1252
Sexual health is an integrated care-delivery and prevention concept that recognizes sexual expression as normative and encompasses preventive and treatment services throughout the life span. However, the United States lacks an integrated approach to sexual health. Public health programs such as sexually transmitted disease (STD)/human immunodeficiency virus (HIV) prevention and family planning are categorically funded and organizationally fragmented, and federal reproductive health programs in the past decade emphasized abstinence. As a result, sexual health indicators are poor.

Abnormal Pap tests after the HPV vaccine

By Leave a Comment

Reprinted from Australian Family Physician Vol. 38, No. 12, December 2009 Stella Heley BA(Hons), MBBS, FAChSHM, is Senior Liaison Physician, Victorian Cytology Service, Melbourne, Victoria. sheley@ vcs.org.au Julia Brotherton BMed(Hons), MPH(Hons), GradDipAppEpi, FAFPHM, is an epidemiologist, National HPV Vaccination Program Register, Victorian Cervical Cytology Registry, Victorian Cytology Service, Melbourne, Victoria. Background Worldwide, cervical cancer affects […]

The Age-Specific Relationships of Abnormal Cytology and Human Papillomavirus DNA Results to the Risk of Cervical Precancer and Cancer

By Leave a Comment

Obstetrics & Gynecology:
July 2010 – Volume 116 – Issue 1 – pp 76-84
doi: 10.1097/AOG.0b013e3181e3e719
Original Research
Castle, Philip E. PhD, MPH; Fetterman, Barbara SCT (ASCP); Thomas Cox, J.; Shaber, Ruth MD; Poitras, Nancy ACS, PMP; Lorey, Thomas MD; Kinney, Walter MD
Abstract

BACKGROUND: To estimate the relationship of human papillomavirus (HPV) detection and abnormal cytology with histologic diagnoses of cervical precancer and cancer.

Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.

By Leave a Comment

Medicine Journal Feeds

Gynecol Oncol. 2010 Aug 14;

Authors: Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK

OBJECTIVE: Testing for human papillomavirus (HPV) 16 and 18 genotypes, which are known to cause approximately 65-70% of invasive cervical cancer cases, may allow clinicians to identify women at highest risk for underlying cervical intraepithelial neoplasia missed by Pap cytology.

News

Videos

Contact